Sirolimus: all 520 studies that test it

Page 2 of 6. Open to participants first (86), then studies with results posted, then the rest; newest registration first within each.

• A Futility Trial of Sirolimus in Multiple System AtrophyTerminatedNCT03589976Phase 2Results posted
• Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney TransplantationCompletedNCT03468478Phase 4Results posted
• Auranofin and Sirolimus in Treating Participants With Ovarian CancerTerminatedNCT03456700Phase 2Results posted
• SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath TumorsCompletedNCT03433183Phase 2Results posted
• Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis ComplexTerminatedNCT03363763Phase 2Results posted
• Discovery of Sirolimus Sensitive Biomarkers in BloodCompletedNCT03304678Phase 2Results posted
• Resveratrol and Sirolimus in Lymphangioleiomyomatosis TrialCompletedNCT03253913Phase 2Results posted
• Sirolimus and Familial Adenomatous Polyposis (FAP)CompletedNCT03095703Phase 2Results posted
• Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell DiseaseActive, not recruitingNCT03077542Phase 1/2Results posted
• Trial of Sirolimus for Cognitive Impairment in Sturge-Weber SyndromeCompletedNCT03047980Phase 2/3Results posted
• Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCTCompletedNCT03018223Phase 1Results posted
• Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive TherapyActive, not recruitingNCT02979873Phase 2Results posted
• Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) StudyCompletedNCT02960997Phase 2Results posted
• A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune SuppressionCompletedNCT02891603Phase 1/2Results posted
• Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the ElderlyCompletedNCT02874924Phase 2Results posted
• A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)CompletedNCT02806947Phase 2Results posted
• Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)CompletedNCT02766465Phase 2Results posted
• Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid NeoplasmsCompletedNCT02756572Phase 2Results posted
• Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMDCompletedNCT02732899Phase 2Results posted
• Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney TransplantationCompletedNCT02711202Not applicableResults posted
• Aging Mammary Stem Cells and Breast Cancer PreventionTerminatedNCT02642094Phase 2Results posted
• PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath TumorsTerminatedNCT02584647Phase 1/2Results posted
• Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid LeukemiaCompletedNCT02583893Phase 2Results posted
• Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate CancerTerminatedNCT02565901Phase 1/2Results posted
• Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula OutcomesCompletedNCT02513303Phase 3Results posted
• Examining the Impact of Sirolimus on Ketamine's Antidepressant EffectsCompletedNCT02487485Phase 2Results posted
• Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)CompletedNCT02440789Phase 1/2Results posted
• Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K ActivationCompletedNCT02428296Phase 2Results posted
• Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMDCompletedNCT02357342Phase 2Results posted
• A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development ProgramCompletedNCT02251938Phase 3Results posted
• Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)CompletedNCT02152007Phase 1Results posted
• An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-DiseaseTerminatedNCT02123966Phase 2Results posted
• A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular TumorsTerminatedNCT02110069Phase 2Results posted
• Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant FailureActive, not recruitingNCT02105766Phase 2Results posted
• SRL (Sirolimus) WithdrawalCompletedNCT02062944Not applicableResults posted
• SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCDTerminatedNCT02013375Phase 2Results posted
• SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)CompletedNCT02008877Phase 1/2Results posted
• Comparing Everolimus and Sirolimus in Renal Transplant RecipientsCompletedNCT01976390Not applicableResults posted
• A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell TumorsTerminatedNCT01962896Phase 2Results posted
• Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder CancerCompletedNCT01938573Phase 1/2Results posted
• Rapalogues for Autism Phenotype in TSC: A Feasibility StudyCompletedNCT01929642Phase 2Results posted
• In Vivo Treg Expansion and Graft-Versus-Host Disease ProphylaxisCompletedNCT01927120Phase 2Results posted
• Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive ChemotherapyCompletedNCT01869114Phase 2Results posted
• Non-Myeloablative Conditioning and Bone Marrow TransplantationActive, not recruitingNCT01850108Not applicableResults posted
• A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue SarcomaTerminatedNCT01842594Phase 2Results posted
• Sirolimus in Kidney Transplant Patients With Squamous Cell Skin CarcinomaTerminatedNCT01764607Phase 2Results posted
• Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung CancerCompletedNCT01737502Phase 1/2Results posted
• Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus ToxicityTerminatedNCT01709136Phase 2/3Results posted
• Using mTOR Inhibitors in the Prevention of BK NephropathyCompletedNCT01649609Not applicableResults posted
• Topical Rapamycin to Erase Angiofibromas in TSCCompletedNCT01526356Phase 2Results posted
• Sirolimus Injections for Autoimmune ScleritisCompletedNCT01517074Phase 1/2Results posted
• In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and SirolimusTerminatedNCT01453140Phase 1/2Results posted
• Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic MemoryCompletedNCT01449955Not applicableResults posted
• Sirolimus for Advanced Age-Related Macular DegenerationCompletedNCT01445548Phase 1/2Results posted
• Study Assessing Double-masked Uveitis TreatmentCompletedNCT01358266Phase 3Results posted
• Research Study of ATG and Rituximab in Renal TransplantationTerminatedNCT01318915Early Phase 1Results posted
• Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis PemphigusTerminatedNCT01313923Early Phase 1Results posted
• Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)TerminatedNCT01303965Phase 1/2Results posted
• A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type FibromatosisCompletedNCT01265030Phase 1/2Results posted
• Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantCompletedNCT01251575Phase 2Results posted
• Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant RecipientsCompletedNCT01236378Phase 1Results posted
• Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell TransplantCompletedNCT01231412Phase 3Results posted
• Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic MalignanciesCompletedNCT01203722Phase 1/2Results posted
• Rapamycin Therapy in Head and Neck Squamous Cell CarcinomaCompletedNCT01195922Phase 1/2Results posted
• Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)CompletedNCT01184898Not applicableResults posted
• A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD ChemotherapyCompletedNCT01184885Early Phase 1Results posted
• Tandem Auto-Allo Transplant for LymphomaCompletedNCT01181271Phase 2Results posted
• Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression-TerminatedNCT01166724Phase 3Results posted
• Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and LymphomaCompletedNCT01162551Phase 2Results posted
• Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)CompletedNCT01134952Phase 4Results posted
• Campath, Calcineurin Inhibitor Reduction and Chronic Allograft NephropathyCompletedNCT01120028Phase 2/3Results posted
• Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell TransplantationTerminatedNCT01116232Phase 2Results posted
• Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)CompletedNCT01106833Phase 2/3Results posted
• Calcineurin Inhibitor Sparing After Kidney TransplantationCompletedNCT01062555Phase 1/2Results posted
• Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01027000Phase 2Results posted
• Sirolimus Conversions in African-American Renal Transplant RecipientsCompletedNCT01005706Not applicableResults posted
• Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or GefitinibCompletedNCT00993499Phase 1Results posted
• Safety and Efficacy Study of Sirolimus in Complicated Vascular AnomaliesCompletedNCT00975819Phase 2Results posted
• Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor SyndromesCompletedNCT00971789Phase 2Results posted
• Polycystic Liver Disease in Kidney TransplantTerminatedNCT00934791Not applicableResults posted
• Tacrolimus to Sirolimus Conversion for Delayed Graft FunctionTerminatedNCT00931255Phase 4Results posted
• Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With LymphomaCompletedNCT00928018Phase 3Results posted
• Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney CancerCompletedNCT00923845Phase 2Results posted
• Sirolimus and Pemetrexed to Treat Non-Small Cell Lung CancerTerminatedNCT00923273Phase 1/2Results posted
• Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to TherapyTerminatedNCT00920309Phase 2/3Results posted
• Sirolimus as Therapeutic Approach to UveitisCompletedNCT00908466Phase 1Results posted
• Kidney Biopsy Controlled Trial of Calcineurin Inhibitor WithdrawalCompletedNCT00896012Phase 4Results posted
• Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant RecipientsCompletedNCT00895583Phase 4Results posted
• Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft RecipientsCompletedNCT00866879Phase 4Results posted
• Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive ProtocolTerminatedNCT00866684Phase 4Results posted
• Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT00803010Phase 2Results posted
• Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)CompletedNCT00795886Phase 2Results posted
• Prospective Study of Rapamycin for the Treatment of SLECompletedNCT00779194Phase 2Results posted
• Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMDCompletedNCT00766649Phase 1/2Results posted
• A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced SarcomaCompletedNCT00743509Phase 2Results posted
• Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving MyforticCompletedNCT00713284Phase 4Results posted
• Sirolimus to Treat Diabetic Macular EdemaCompletedNCT00711490Phase 1/2Results posted
• Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma MultiformeCompletedNCT00672243Phase 2Results posted
• Raptiva and Sirolimus in Islet Transplantation for Type 1 DiabetesTerminatedNCT00672204Phase 1/2Results posted
• A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform NeurofibromasCompletedNCT00634270Phase 2Results posted

← Sirolimus overview